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ABSTRACT
CYSTEINE DIOXYGENASE: THE IMPORTANCE OF KEY RESIDUES AND
INSIGHT INTO THE MECHANISM OF THE METAL CENTER

MAY 2008
JONATHAN H. LEUNG, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Michael J. Maroney

Cysteine dioxygenase (CDO) is a non-heme iron enzyme that can be found in
mammalian tissue. It is mainly localized in the liver but is also present in the brain,
kidney, and adipose tissue. CDO converts cysteine to cysteine sulfinic acid, which is the
first step in cysteine metabolism in the human body. CDO contains a novel cofactor
located near the metal binding site that is present in another enzyme, galactose oxidase,
where it is essential for redox function. This suggests that the linkage may play an
important role in CDO as well. The cofactor consists of Y157 and C93. Mutation of the
C93S causes a drop in activity to 57.1% and a mutation of the Y157F causes a drop to
8.1%. The metal center was studied using XAS revealing that the addition of cysteamine,
an activator of CDO, changes the conformation of the binding site significantly. CDO
differs from the rest of the cupin super family in that it does not contain a 2-his-1carboxylate binding motif but rather the carboxylate is replaced with another histidine. A
mutation of one of the binding residues, H140D, caused the enzyme to be non-active.
Also the mechanism of the CDO was studied by conducting activity assays with various
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inhibitors and activators that yielded contradicting results with previously published
work.
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CHAPTER 1
CYSTEINE DIOXYGENASE
1.1 Introduction to Cysteine Dioxygenase
Cysteine dioxygenase (CDO) catalyzes the reaction of cysteine to cysteine
sulfinic acid (CSA) by adding molecular oxygen to the thiol of cysteine (Figure 1.1).
This reaction is the first step in the cysteine catabolic pathway. CDO plays a key role
in maintaining intracellular sulfur concentrations. As such, CDO is mainly found in
the liver, but appreciable amounts can also be found in the kidney, brain, lungs, and
adipose tissue.1,2,3 CDO has such a large impact on maintaining intracellular sulfur
concentrations it can decrease steady state intracellular cysteine levels as well as
glutathione levels.4 High levels of cysteine are associated with the neurological
diseases Alzheimer’s and Parkinson’s diseases.5 Abnormal CDO activity and the
accumulation of cysteine have been observed in patients suffering from the
neurological disorder Hallervorden-Spatz syndrome.6 CDO may directly affect the
disease cystinosis. Cystinosis occurs when cysteine builds up and it begins to form
disulfide bonds with each other forming the insoluble compound cystine.7,8 CDO
eliminates excess cysteine to avoid this condition.

Figure 1.1. The conversion of cysteine to cysteine sulfinic (CSA) acid by CDO
After CSA is made it can undergo two major pathways, one ultimately
resulting in taurine formation and the other creating pyruvate and sulfate. The taurine
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pathway involves the decarboxylation of CSA by the enzyme cysteine sulfinate
decarboxylate to form hypotaurine (2-aminoethane sulfonate).9 Hypotaurine is then
oxidized to taurine via a poorly understood pathway where enzymatic and nonenzymatic mechanisms may occur.10 CSA can undergo a second pathways where
transamination occurs to form β-sulfinylpyruvate, which spontaneously decomposes
to sulfite and pyruvate.11 Sulfite readily oxidizes to sulfate. Lack of cellular sulfate
has also been associated with rheumatoid arthritis.12
CDO is a Fe(II) non-heme iron dioxygenase and contains significant sequence
homology with other members of the cupin superfamily of proteins.13 Members of
this superfamily possess a ß-barrel with a jelly roll topology which can also be seen in the
crystal structure (Figure 1.3).13 Members of this family contain two conserved sequence
motifs, G(X)5H(X)H(X)3,4E(X)6G and G(X)5P(X)G(X)2H(X)3N (Figure 1.2), derived from the
superfamily archetype, germin.14 The second sequence is less conserved than the first. The
active site of these proteins are usually formed by a histidine and a carboxylate residue, either
glutamate or aspartate, from the first motif and another histidine from the second motif
forming the 2-his-1-carboxylate binding motif common among Cupin members. In CDO

the carboxylate residue is replaced with another histidine forming a 3-histidine
binding pocket.
-35

MGSSHHHHHH SSGLVPRGSH MLEGWTEETR PSPAG

0
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100
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NLKETLFDWPDKKSNEMIKKSERTLRENQCAYINDSIGLHRVENVSHTEP

150

151

AVSLHLYSPPFDTCHAFDQRTGHKNKVTMTFHSKFGIRTPFTTSGSLENN

200

Figure 1.2. Amino acid sequence of recombinant CDO. Residues -35 to 0 represent
the 6x histidine tag used for purification. Residues in green are conserved residues
through out other CDOs in other organisms near the metal binding site. Residues in
red represent the three metal binding histidines.
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Figure 1.3. Crystal structure of rat CDO showing the typical jelly roll beta barrel.
(PDB ID 2GH2)
Four crystal structures of CDO have been resolved, three eukaryotic and one
prokaryotic. These proteins came from mouse, rat, human, and Ralstonia eutropha
(Figure 1.4).15,16,17,18 All the crystal structures show different binding geometries with
different bound molecules but all contain the 3-histidine metal binding site. The
mouse protein had nickel bound to the active site and was octahedral with the three
histidines arranged as a facial triad with aqua molecules opposing them.15 Then the
rat structure was modeled with an iron bound to one aqua ligand and the three
histidines in a tetrahedral formation.16 The other two structures were modeled with
iron and found to be 5-coordinate with a cysteine or two aqua molecules in the human
and bacterial enzymes respectively.17,18
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Figure 1.4. Metal binding sites of the four solved CDO crystal structures. (A) Mouse
with Ni(II) bound (2ATF). (B) Rat with Fe(III) bound (2B5H). (C) Human with
Fe(II) bound and cysteine in the binding site (2IC1). (D) The bacterial Ralstonia
Eutropha with Fe(III) bound with a sulfate in the binding site (2GM6).
The prokaryotic CDO also contains another unique feature from the other
crystal structures. All but the bacterial structure reveals a novel cysteinyltyrosine
cofactor. In the prokaryotic CDO the bridging cysteine is replaced by a glycine,
disrupting the linkage.18 This linkage is well characterized in only one other enzyme,
galactose oxidase. In galactose oxidase the linkage is required for enzyme
functionality where it serves as an internal redox cofactor.19 Using site directed
mutagenesis it was possible to convert cysteine-93 and tyrosine-157 to a serine and
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phenylalanine respectively. With these mutations it is possible to study the
importance of these residues and if the residues or the linkage between them are
required for catalysis.
Another novel feature of CDO is the 3-histidine metal binding site only shared
by a few other members of the cupin superfamily such as diketone dioxygenase.20
The more common 2-his-1-carboxyl binding motif is found amongst most of the
Cupin superfamily. This motif is found to bind many more metals than iron while still
yielding functional enzyme where as the 3-histidine motif does bind many various
metals,20 but only when Fe(II) is bound to the active site is functional enzyme is
yielded. Again, using site-directed mutagenesis the 2-his-1-carboxyl motif will be
restored and its affects on CDO will be assessed.
More insight into the mechanism and binding pocket of CDO is found by
using x-ray spectroscopic techniques. Using extended x-ray absorption fine structure
(EXAFS) it will be possible to see what geometry around the metal center is formed
in unbound substrate, bound substrate, and bound with the activator cysteamine. It
will give information about how the substrate binds whether it is by the carboxyl,
amino, thiol or if the substrate is bound directly to the iron at all. The ligand distances
around the iron will be found and used to determine possible functions of the various
residues located around the metal.
1.2 Experimental
1.2.1 Over Expression in Escherichia Coli
Recombinant rat CDO-ORF was previously subcloned into the vector pET14b and transferred into the E. Coli strain BL21(D3)pLysS. The cells are grown in
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LB broth at 22 oC for 8 hours. At this time the expression of CDO is induced by
addition of IPTG and ferrous ammonium sulfate to a final concentration of 200 μM
each. Then the cells were grown for an additional 16 hours at 22 oC.
Cells were harvested by centrifugation and resuspended in 50 mM Phosphate,
pH 8.0, also containing 300mM sodium chloride buffer and 10 mM imidazole. This
suspension is kept frozen in a –20 oC freezer for future analysis. The cells are lysed
by thawing in the presence of phenylmethylsulfonyl fluoride (PMSF) and
Benzonuclease. SDS-PAGE using the Laemmli method is used to confirm the
expression of CDO.21
1.2.2 Purification of Recombinant CDO
The cell lysis is centrifuged to pellet the solid cell debris. The recombinant
CDO contains an extra 35 amino acid his-tag sequence attached to the N-terminal end
of the protein. The supernatant was ran over a nickel-nitrilotriacetic acid (NTA)
column and the nickel will bind the his-tag of CDO purifying it from other impurities.
The bound protein is washed with 1.5 L of 50 mM phosphate buffer, pH 8.0,
containing 300mM sodium chloride and 30mM imidazole. After washing, the protein
is eluted from the column with a 50mM phosphate buffer, pH 8.0, containing 300mM
sodium chloride and 300mM imidazole. SDS-PAGE with the Laemmli method is
used again to confirm that pure protein was eluted from column (Figure 1.5).21
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Figure 1.5. SDS-PAGE gel after CDO purification. (Lane 1) Marker. (Lanes 2-7)
elutions 1-6 from NTA column. (Lane 8) Cell lysis with CDO removed. The last
marker represents 24 kDa.
The elution is then concentrated with 10,000 Da cutoff 5 mL spin
concentrators to a final protein concentration of approximately 100 μM and then
buffer exchanged into 50 mM phosphate or HEPES buffer, pH 7.5 containing 100mM
sodium chloride. The iron content of the sample is determined by ICP-OES in the
same buffer and the final concentration of the sample is determined with bicinchonic
acid (BCA) protein assay (Pierce).
1.2.3 Activity Assay
A water bath is preheated to 37oC. 1.5 mL centrifuge tubes (epi-tubes) were
filled with varying substances depending on the test being performed. A standard test
with CDO saturated for Vmax determination includes 50 μL of CDO and 950 μL of 30
mM cysteine for final concentrations of 4.5 μM and 23.2 mM respectively. The tubes
were incubated in the water bath for 3.5-5 hours. After this, the reactions were
stopped by the addition of 20 μL of heptafluorobutyric acid (HFBA) to each epi-tube.
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The HFBA causes the CDO to precipitate out of solution. The CDO was pelleted with
centrifugation and the supernatant was aliquoted into a separate high performance
liquid chromatography (HPLC) vial. Analyses of the samples were done in two ways,
HPLC and induced coupled plasma with optical emission spectra (ICP-OES).22
1.2.4 Activity Analysis of CDO
1.2.4.1 Use of High Performance Liquid Chromatograph (HPLC)
The mobile phase that was used is a 99.4:0.6 (v/v) ratio of water:methanol
solution containing 3% HFBA. Flow conditions were 50 μL of sample injected at a
flow rate of 0.8 mL/min for 20 minutes. Two Agilent C18 columns were used for
separation. Detection of substances were done by the use of a ultra-violet light
detector at the wavelengths 215nm and 230nm (Figure 1.6).22

0.5

CSA

Buffer

Cysteine

Absorption

Cystine
0.0
HFBA
-0.5

CSA Control
Wild Type CDO

-1.0

4

6

8

10

Time (min)

12

14

16

Figure 1.6. Activity assay chromatogram from HPLC. Absorption is at 215 nm.
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1.2.4.2 Use of Induced coupled plasma with optical emissions spectra (ICP-OES)
The same mobile phase for ICP-OES is used as in the HPLC analysis. Flow rate on
the ICP-OES was set at 1 mL/min and was ran for 10 minutes. Only one Agilent C18
column is needed for separation. The detector was set for a sulfur emission line at a
wavelength of 181.975nm (Figure 1.7).

Figure 1.7. Activity Assay chromatogram from ICP-OES.

1.2.5 Cleavage of His-tag from Recombinant CDO
Thrombin attached to agarose beads were washed three times with a 1x
cleavage buffer (50 mM Tris-HCl, pH 8.0, 10 mM CaCl2) by using centrifugation and
then decanting the supernatant. The CDO was buffer exchanged into 1x cleavage
buffer. 1 mg of CDO was added to an epi-tube along with 100 μL of 10x cleavage
buffer. This solution was diluted to 1 mL with DI water. The solution was placed on a
rotating platform to flip and agitate the solution for 24 hrs. The cleaved protein was
retrieved by the same method as the wash except the supernatant is decanted into a
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separate epi-tube and stored at 4 oC. Confirmation of cleavage is done by SDS-PAGE
looking for a band at 23 kDa.
1.3 Results and Discussion
The expression of the recombinant enzyme was confirmed by SDS-PAGE.
The SDS-PAGE clearly shows a thick band slightly above the 24 kDa marker. This
band represents CDO with a histidine tag. The elution of CDO from the Ni-NTA
column is done in six 10 mL aliquots. Most of the CDO is concentrated in the second
aliquot, but reasonable amounts are distributed among the first, third, and fourth as
well. (Figure 1.5) The purpose of the fifth and sixth aliquots is to make sure all CDO
has been eluted. The gel also detects a high molecular weight peptide. It is unclear
what this band is. The protein is still quite pure because the band is faint and does not
represent much protein. It is possible that this peptide could represent the 68kDa sized
CDO protein that was found by Waring and co-workers. This protein found by
Waring did not dissociate under reducing conditions with SDS or with boiling.23,24
The eluted protein is concentrated using 10 kDa spin concentrators. Then it is
buffer exchanged. At first a phosphate buffer pH 7.5 containing 100mM sodium
chloride was used because it was most stable in that buffer but then it was found to be
also stable in HEPES buffer pH 7.5 containing 100mM sodium chloride, so HEPES
buffer was then used. HEPES buffer was chosen over phosphate buffer because of the
convenience for metalation and thrombin cleavage. The samples of protein come out
to an approximate volume of 2 mL and concentration of 100 μM per liter of culture.
This varies from purification to purification. The sample is tested for activity, which
can be seen in the chromatograms above (Figure 1.6 and 1.7). Iron content of the
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CDO samples have an average of 10%, but have been as low as 6%. Recently it was
possible to incorporate 26% iron into the enzyme using a slightly modified metalation
scheme by ripping out other metals by chelation with EDTA and adding iron
ammonium sulfate to the final purified product under anaerobic conditions
When enzyme is confirmed for purity and activity it may be cleaved to
remove the histidine-tag. The purpose of this is to increase maximum concentration
that CDO can achieve without precipitating out of solution. Increased concentrations
are needed for several of the following experiments described later such as X-ray
Absorption Spectra (XAS). Also thrombin cleavage is needed to prepare enzyme for
crystallization because the native enzyme is needed.
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CHAPTER 2
MUTATION OF THE CYSTEINLYTYROSINE COFACTOR IN CYSTEINE
DIOXYGENASE
2.1 Introduction
One class of enzyme cofactors arises from covalent modifications of amino
acid side chains. A common example of this is a disulfide bond between two
cysteines due to the spontaneous oxidation of the thiol in the presence of oxygen.
There are other examples of covalent cofactors but are usually rare. These include the
cysteinyltyrosine thioether bond in galactose oxidase, tyrosine-histidine bond in
cytochrome C oxidase, tryptophan-tryptophan bond in methylamine dehydrogenase,
histidine-cysteine bridge in catechol oxidase, and 2,4,5-trihydroxyphenylalanine
quinine in copper amine oxidase.1,2,3,4,5 All of the cofactors in these enzymes serve as
redox active amino acids.6

Figure 2.1. The metal binding site with iron bound, but clearly showing the
cysteinyltyrosine cofactor on the upper left.
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As mentioned before, in section 1.1, four crystal structures have been solved
and three of the four contain a cysteinyltyrosine cofactor (Figure 2.1), this puts CDO
into a short list of enzymes that contain cofactors.7,8,9 This thioether cofactor is very
rare and is only well characterized in one other enzyme, galactose oxidase (Figure
2.2).10 It is thought it is also present in glyoxal oxidase, but is only characterized
through resonance Raman spectroscopy and optical absorption spectra.11 In galactose
oxidase, the cofactor is redox active and a copper ligand.10 The bridging bond is a
post-translational modification. It has been shown that if this modification does not
occur, the enzyme is non-functional.10

Figure 2.2 Metal Binding site of galactose oxidase. The copper is bound by Tyr272,
Tyr495, His496, and His581. Tyr272 is also involved in a thioether bond with
Cys228.
It is possible that the cofactor in CDO serves a purpose similar to that of
galactose oxidase. It is believed that the cofactor most likely does not serve as a
reducing agent because the cysteinyltyrosine does not exist in the bacterial CDO
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crystal structure, where the cysteine is replaced by a glycine.12 Thus, despite the lack
of the cofactor, the enzyme is able to function as a dioxygenase. Instead the
cysteinyltyrosine may serve as an intermediate stabilizer during the reaction
mechanism through hydrogen bonding. The following mutagenesis experiments were
performed to determine the function of the cofactor and help characterize CDO’s
mechanism and unique structure.
2.2 Experimental
2.2.1 Mutation of the Cysteinyltyrosine Cofactor
Two mutations were done for the characterization of cysteinlytyrosine. These
mutations were C93S and Y157F. They were made using site-directed mutagenesis.
The DNA plasmid, pET-14b containing the recombinant rat CDO-ORF, was isolated
from E. Coli BL21(D3)pLysS cells that contained it using a miniprep assay (Qiagen).
Reverse transcription polymerase chain reaction was performed using the respective
primers for each mutation (Table 2.1). Confirmation of the mutation was performed
by DNA sequencing obtained at Keck laboratory in Yale. When the mutation was
confirmed, the mutated plasmid was transformed into the super-competent cell line,
Nova Blue, and plated on LB containing ampicillin.
Table 2.1. Primer sequence for the cysteinyltyrosine cofactor mutations
Mutation
Forward Primer
Reverse Primer
C93S

3’-cac acg gac tcc cac tcc ttt ttg 3’-cag cag ctt caa aaa gga gtg gga
aag ctg ctg-5’
gtc cgt gtg-5’
Y157F
3’-gtg agc ctt cac ttg ttc agt cca 3’-gt atc gaa agg tgg act gaa caa gtg
cct ttc gat ac-5’
aag gct cac-5’
A culture of Nova Blue cells were grown in LB broth containing ampicillin
overnight and subsequently pelleted and miniprepped. The DNA from the miniprep
was transformed into BL21(D3)pLysS cells and plated. Finally overnight cultures
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were grown in LB broth containing ampicillin and chloramphenicol and then samples
were flash frozen in cryogenic tubes with liquid nitrogen and stored in a -80oC freezer
as a cell stock.
2.2.2 Michaelis Menten Kinetics of the Mutants
Assay conditions similar to those of the standard activity assay described in
section 1.2.3 were used to assay the mutant enzymes. Eight reactions were performed
per mutant with the cysteine concentrations varying from 0-23mM. Assays are
analyzed as described above in section 1.2.4 and the results are plotted with cysteine
versus enzyme activity.
2.3 Results
Two mutations were made to test the importance of the cysteinyltyrosine
cofactor, C93S and Y157F. Both of these mutations disrupt the covalent bond and
were chosen because the residues best replace the existing residues in terms of size
and chemistry. Figure 2.3 shows the results plotted as a Michaelis Menten graph,
which then can be seen summarized in table 2.2. The activity is normalized to iron
content because enzyme is only active when iron is incorporated in the active site.
Since CDO only binds about 10% and that number varies from samples to sample,
each of the activities need to be normalized to get the true activity.
Table 2.2. Table of activities for cysteinyltyrosine mutants normalized to iron
content.
Sample
Activity (mol
Percent Activity
Km (mM)
kcat/Km
(M-1 s-1)
CSA/min/mol Fe) (compared to wild
type)
Wild Type
41.8±7.3
100%
1.8±0.2
1.3E3±0.5
C93S
23.9±4.5
57.2%
1.6±0.2
7.8E2±0.5
Y157F
3.4±0.3
8.1%
.17±0.01
1.0E3±0.3
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Figure 2.3. Michaelis Menten graph of cysteinyltyrosine mutants.

2.4 Discussion
The results show that the cysteinyltyrosine is not required for activity in
context to its role in galactose oxidase. In galactose oxidase if the cofactor is
disrupted in any way then the enzyme is no longer active.10 In CDO, the elimination
of the cofactor in the C93S mutant caused a decrease in activity of 42.8%. Also
Y157F, which changed the residue closest to the metal center, still had 8.1% activity.
Although this is a significant drop in activity, it proves that the cofactor is not
required for activity. Instead each of the residues involved serve different purposes.
The large drop in activity due to the loss of the tyrosine may suggest that it is
involved in forming the enzyme substrate complex. The hydroxyl group may serve as
a hydrogen bond donor or proton donor to help stabilize the intermediates. The
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cysteine has a less important role. The cofactor provided by the cysteine appears to be
merely a stabilizing bridge for the more important tyrosine. When the cysteine is
removed, the cofactor breaks and the tyrosine is less rigid. Less rigidity means that
the tyrosine can move and “flop” around causing it to adopt conformations that some
of the time don’t stabilize the intermediates, thus the reaction goes slower. The
function of the cysteine would then be to hold the tyrosine in place. This forces the
hydroxyl group to point directly to a pocket in the metal center where the substrate
may bind.
The less crucial role of the cysteine explains why it doesn’t exist in the
bacterial enzyme but the tyrosine does. The reason for this evolutionary difference in
enzyme structure maybe because full activity of the enzyme is not needed. Having the
fully functional enzyme as it exists in mammals may be detrimental to the bacteria
because too much cysteine would be converted to CSA leaving too little for other
functions such as other protein expression. For the bacterial enzyme from Ralstonia
eurtropha, the tyrosine by it self has enough activity for its function.
Overall the characterization of the cysteinyltyrosine cofactor gives some
insight into the mechanism of the reaction and more information on how the
oxygenases of the cupin superfamily function.
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CHAPTER 3
PROBING THE 2-HISTIDINE-1-CARBOXYLATE MOTIF OF THE CUPIN
SUPERFAMILY
3.1 Introduction
As mentioned above, the cupin super family typically contains a 2-histidine-1carboxylate motif, but there are variations to this.1 For instance, Quercetin
Dioxygenase (QDO) contains a 3-histidine-1-carboxlyate binding pocket.2 Most
importantly to this thesis is the 3-histidine motif of CDO. It has been shown that most
non-heme iron oxygenases of the 2-histidine-1-carboxylate motif also require αketoglutarate as a co-substrate.3 α-ketoglutarate acts as a co-substrate and accepts one
of the oxygen atoms and decomposes to carbon dioxide and succinate.3 This is
coupled with the oxidation of the main substrate.3 These α-ketoglutarate dependent
enzymes catalyze a diverse amount of reactions like side-chain modifications,
DNA/RNA repair, metabolism, and degredation of many compounds.3
The source of power for the catalysis of these reactions is believed to come
from oxygen activation.4 Here it is hoped to elucidate the mechanism by which CDO
catalyzes its reaction. CDO is not a α-ketoglutarate dependent oxygenase and it
contains a unique binding pocket. The differences in CDO compared to the other
members of the cupin superfamily suggest it reacts differently. This means there are
no significant clues into how the mechanism of CDO works. Also the sulfur on the
cysteine readily oxidizes; this suggests that the sulfur does not need a strong
oxidizing agent for the reaction to occur.
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The following experiments hope to elucidate some of the mechanism by
mutating one of the histidines in the binding pocket to a carboxylic amino acid. The
carboxyl group of the amino acid should provide the iron atom with more oxygen
activating potential. If CDO undergoes oxygen activation as a part of its mechanism,
then CDO should still be able to catalyze its reaction.
3.2 Experimental
3.2.1 Creating the 2-Histidine-1-Carboxylate motif through mutation
Site-directed mutagenesis is performed using the same protocol as described
in chapter 3 when creating the cysteinyltyrosine mutations. In the cysteinyltyrosine
mutants it was possible to use the mixture of pLysS and pET-14b vectors. The pET14b vector contains the CDO-ORF and the pLysS vector comes in all the
BL21(D3)pLysS cells. In the case of H140D the RT-PCR did not work with the
mixture, so the pET-14b vector which contained the CDO-ORF had to be purified
alone.
To do this DNA purification, both plasmids were isolated using the “DNA
miniprep kit” (Qiagen) from frozen cell stocks of BL21(D3)pLysS cells containing
the pET-14b vector. The plasmid mixture was transformed into Nova Blue cells and
grown on LB plates with ampicillin. The controls were cells grown on plates with no
drugs and plates with ampicillin and chloramphenicol. A colony from the ampicillin
only plate is taken and a 5 mL overnight culture was made. This DNA from the
culture was isolated and the procedure was repeated. This was repeated until colonies
grow on the ampicillin plate and no drug plate but not the ampicillin and
chloramphenicol. When the colony no longer grows on the dual drug plate, then the
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colonies on the ampicillin-only plate contained the pET-14b vector and not the pLysS
vector.
After the pET-14b vector is purified then the mutagenesis can be performed as
described above in chapter 3. The forward primer for H140D is 3’-gat tct att ggc tta
gat cga gta gag aac gtc agc c-5’ and the reverse primer is 3’-g gct gac gtt ctc tac tcg
atc taa gcc aat aga atc-5’.
3.2.2 Characterizing H140D
3.2.2.1 Activity analysis
Assay is conducted as the standard assay described above. 50 μL of H140D
CDO is added to an epi-tube to a final concentration of 4.9 μM after the addition of
cysteine. 950 μL of Cysteine is also added for a final concentration of 18.7 mM and
total volume of 1 mL.
3.2.2.2 Metal analysis
Metal analysis was performed on an ICP-OES. Samples were injected into the
nebulizer and analyzed for iron content at the wavelength 238.208 nm. Iron content
was then compared to protein concentration to obtain percent iron content.
3.3 Results
H140D was created as the first of three of mutations of the metal binding site
that will mimic the 2-his-1-carboxylate motif. This is important because most of the
other members of the cupin super family have a 2-his-1-carboxylate motif. The
results from this mutation showed that H140D is required for activity and replacing it
with an aspartate kills activity. It can be seen in the chromatogram below that H140D
lacks the CSA peak (Figure 3.1).
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Figure 3.1. HPLC chromatogram with UV detection at 215 nm. The H140D
chromatogram clearly shows no CSA peak is present, whereas wild type CDO does
have a CSA peak.
3.4 Discussion
To begin the characterization of H140D it was first analyzed for activity.
When looking at the HPLC chromatogram it can be easily seen that no CSA is
produced under conditions where WT does have product. This peak normally elutes
at around 6.5 minutes. If CSA is formed, it is due to the spontaneous oxidation of the
thiol of cysteine naturally. This amount of CSA that is naturally formed under these
conditions is not detectable. H140D binds approximately 7% ferrous, so it is known
that the lack of activity is not caused by the lack of iron incorporation.
Since the mutant was found to be inactive it suggests that CDO may not
undergo oxygen activation. The reasoning behind this theory is supported by the fact
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that when the carboxylate is introduced into the metal binding center it would add
more electron density to the iron. This would cause more oxygen activating potential
for the iron. If the mechanism of the CDO reaction goes via oxygen activation then
the addition of the carboxylate might increase enzyme activity instead of killing it.
Also in nature the thiol of the cysteine substrate becomes oxidized very easily and in
fact CSA is formed naturally as mentioned before. Usually the oxidation of the thiol
results in a disulfide bond with another cysteine, forming cystine. Since the thiol
oxidizes easily, oxygen activation is not necessarily needed to perform the reaction
that CDO catalyzes. Thus, CDO is present for a different reason other than activating
oxygen for attack on cysteine.
It is possible that since CDO has a unique binding pocket that it also reacts
uniquely. Since CDO does not use oxygen activation it is possible that CDO may
react via a substrate activating pathway where a sulfur radical develops and attacks
the oxygen to form the sulfur-peroxo intermediate.
Next step for characterization of H140D requires a return to Stanford for XAS
analysis. Samples have been prepared but yet to be analyzed due to time constraints
on the beam line.
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CHAPTER 4
XAS STUDIES OF THE METAL BINDING SITE OF CYSTEINE
DIOXYGENASE
4.1 Introduction to XAS Techniques
X-ray absorption spectroscopic (XAS) techniques are used to determine the
local structure of the metal site. The two specific regions of the XAS spectra that
were used in this study were extended x-ray absorption fine structure (EXAFS) and xray absorption near edge spectra (XANES). Each spectrum tells a different story.
Coordination number and geometry can be determined by XANES analysis of
features found below the edge energy. EXAFS is found above the edge and can be
used to determine bond lengths and what type of atom the metal is bonded to.
The theory behind XANES involves an x-ray tuned to the absorption energy
of the core electron of the element being analyzed. The atom absorbs the x-ray and a
core electron is excited. The edge corresponds to the energy at which the electron is
ejected. This is referred to as the white line. Pre-edge features correspond to highenergy electron transitions such as a 1s→3d transition. The area of this peak contains
information on what the coordination geometry of the target atom maybe.1
The EXAFS region begins at about 200eV above the edge. The ejected
photoelectron has inherent wave properties that give rise to constructive and
destructive interference with photoelectron waves that are backscattered from nearby
atoms.1 Using the equation below it is possible to extrapolate information about the
metal center of the enzyme from the EXAFS.2 Figure 4.1 outlines what information
comes from which parts of the EXAFS more simply.2
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Table 4.1 Variables and their meanings to the equation above
Variable
Meaning
Number of scattering atoms in the shell
Ns
| fs(π,k) |
Inherent backscattering amplitude for this type of scattering atom
Distance between absorbing atom and the scattering atoms in this
Ras
shell (Å)
Mean free path for inelastic scattering of photo electrons (Å)
λf
σas2
The rms deviation of Rasexp(-2 σas2k2) is referred to as the DebyeWaller factor
The inherent backscattering phase shift for this
αas(k)
absorbing/scattering atom combination.

Frequency

Distance

Amplitude

Coordination number

Phase

Atom type

Figure 4.1 Simplified outline of EXAFS features and the information obtained from
them.
XAS is typically done at synchrotron sources because a variable x-ray source
is needed as well as high intensities. Several are located around the world. The CDO
XAS experiments were performed at Stanford University using the SSRL beam-line
9-3.
4.2 Experimental
4.2.1 XAS sample preparation
Sample preparation was done in anaerobic conditions. The thrombin cleaved
CDO from the protocol in section 1.2.5 was reconstituted with Fe (II) ammonium
sulfate. The CDO is in 50mM HEPES, pH 7.5 and contains 100 mM NaCl. EDTA
was added to the sample of CDO and allowed to sit for one hour before being
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removed by buffer exchange. Iron was added to a final concentration that was twice
that of the concentration of CDO and allowed to sit for 2 hours and then chelexed and
buffer exchanged to remove excess iron. The CDO was 217 μM and thus the final
concentration of iron during reconstitution was 434 μM. The CDO was then
concentrated to 500 μM.
30 μL of the CDO is aliquoted into an epi-tube with 1 μL of a 62 mM
solution of cysteine for a final concentration of 2 mM cysteine. Another sample
prepared with just the activator, cysteamine, was made the same way but with a 62
mM solution of cysteamine. A control sample was also made without substrate or
activator. Sample analysis was performed at Stanford University at the SSRL beam
line 9-3. Other iron samples that were made for a second trip to the beam line include
the mutant H140D and H140D with cysteine. These samples were prepared using
cleaved H140D CDO and used the same procedures as above except using mutant
cleaved CDO instead. Some nickel samples were also prepared by using nickel
chloride in place of the ferrous ammonium sulfate during metal reconstitution. These
samples include Ni-CDO and Ni-CDO with cysteine. Metal content was determined
after samples were analyzed by XAS. This is done on the ICP-OES
4.2.2 XAS analysis methods
Sample analysis was performed at Stanford University at the SSRL beam line
9-3. Analysis was done at 10 K using a liquid helium cryostat. The ring conditions
were 3 GeV and 80-100 mA. The optics consisted of a Si(220) double-crystal
monochromator and two rhodium coated mirrors. A flat mirror before the
monochromator was used for harmonic rejection and vertical collimation, and a
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toroidal mirror after the monochromator was for focusing. The detector at this
beamline was a 30-element germanium detector (Canberra). A set of soller slits with a
Z-1 element filter was placed between the sample chamber and detector to minimize
scattering. XANES was collected from ±200 eV relative to the edge. EXAFS was
collected from 13.5-16 K above the edge energy.3
4.3 Results
The EXAFS that was obtained from the beam trip did not have good enough
signal to noise ratio for analysis due to low metalated CDO concentration. However,
there was some useful data obtained from the XANES spectra. It can be seen that the
sample that contained the activator cysteamine was very different than the CDO
sample and the CDO with substrate sample. The differences can be seen in the 1s →
3d transition peak area as well as the white line intensity at approximately 7135 eV
(figure 4.2).
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Figure 4.2 XANES spectra clearly showing large differences in 1s → 3d and edge
peak intensities.
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To ensure that metal concentrations are high enough for analysis by XAS,
metal analysis was done on the samples post analysis. The metal content of the
samples that were analyzed were all 12% of enzyme had iron bound. This means that
the iron concentration was approximately 60 μM because the protein was 500 μM.
Metal analysis on samples that were not analyzed by XAS was not performed yet.
There is a limited amount of protein when making samples due to low protein
expression and slow protein cleavage thus all protein that is cleaved is used to make
samples. Only after the samples are analyzed by XAS then can be used to determine
metal analysis because samples are not retrievable after analysis with ICP-OES.
4.4 Discussion
To further elucidate the coordination number and binding geometry of the
metal binding site of CDO, the power of x-ray absorption spectroscopy was used. The
purpose of the technique was to determine the geometry of the binding site, what
ligands bind the iron center, and their distances from the iron. When looking at the
results for the three samples that were analyzed it can be seen easily that the
cysteamine XANES is quite different than the other two. The enzyme and the
enzyme/substrate complex look very similar which confers with prior results obtained
previously. Also it was previously found that the substrate does not bind by the thiol.
It is suggested that the substrate may not bind to the iron at all, which is supported by
the results since there is so little change in the XANES spectra.
Unfortunately no conclusive data can be determined from the EXAFS of the
three samples. There was a great amount of noise past 3.5 Å and it is unclear what
peaks were noise and what may be data. Previous experiments by a former student
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showed similar XANES spectra and the EXAFS from these showed six N/O ligands
on samples of CDO without cysteine and CDO with cysteine (figure 4.3)4.

Figure 4.3. EXAFS and XANES of CDO without cysteine (A, solid line) and with
cysteine (B, dotted line) showing a white line around 7128 eV. The Fourier transform
show 6 N/O donors on both samples.4
More samples of for XAS analysis were made but due to time constraints they
were not analyzed. The unique mutant H140D was made to probe the metal binding
site and to see if there is a change in binding coordination from wild-type CDO.
H140D is the first of a series of mutants made to mimic the 2-histidine-1-carboxylate
motif that most other members of the cupin superfamily of oxygenases. This motif is
interesting because most other members with this motif also require α-ketoglutarate
where it acts as a reducing agent. Also these enzymes with the 2-histidine-1carboxylate motif undergo oxygen activation. Nickel samples were also made and not
analyzed. These include nickelated CDO and nickelated CDO with cysteine bound.
The purposes of these were to see if nickel changes the coordination number and
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geometry of the metal binding site. Also to see if there are any changes in the way the
substrate may bind to this alternate although non-active metal.
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CHAPTER 5
CDO ACTIVITY INHIBITORS REVISISTED
5.1 Introduction
Sergio Chai, a former student of the lab, tested several compounds to see their
effect on CDO activity. Some of these compounds were found to be inhibitors of
CDO. These included homocysteine, mercaptopropionic acid, aspartic acid, αketoglutarate, and S-carboxymethyl-cysteine.1 The common factor between these
compounds is that they are structural analogs of cysteine and also contain a
negatively charged side chain.1 Other compounds were tested that did not have
negative side chains and were not found to be inhibitors.1
CDO was the first non-heme iron dioxygenase that was discovered to be
inhibited by α-ketoglutarate. In fact other non-heme iron dioxygenases use αketoglutarate as a co-substrate.2 These oxygenases are known as intermolecular
dioxygenases where one oxygen atom is inserted into the substrate and the other
oxygen is added to the α-ketoglutarate.2 It is clear that CDO is not an intermolecular
dioxygenase because it utilizes both oxygen atoms in its reaction.
In this chapter we will be revisiting the inhibitors that were tested previously.
It was found that aspartate in particular inhibited CDO by about 50%. The previous
inhibition experiments were conducted in phosphate buffer (50 mM phosphate pH
7.5, 100 mM NaCl). Also as well as phosphate, ammonium acetate solution (50 mM
ammonium acetate, pH 7.5, 100 mM NaCl) was also used for other experiments. As
mentioned before, experiments have changed to be conducted in HEPES buffer (50
mM Hepes, pH 7.5, 100 mM NaCl) due to solubility problems when using phosphate
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buffer. Phosphate salts are insoluble when they form the compounds ferrous
phosphate and calcium phosphate.
Retesting of aspartate as an inhibitor was needed to determine what class of
inhibitor it was. This experiment was conducted in HEPES buffer instead of
phosphate buffer and a surprising result occurred. Aspartate caused an increase in
CDO activity instead of inhibiting it. These results stimulated new experiments to
elucidate why aspartate acts as an inhibitor in phosphate buffer but an activator in
HEPES buffer.
5.2 Experimental
5.2.1 Aspartate inhibition assay
This was an assay to determine what type of inhibitor aspartate was. The assay
conditions used HEPES buffer (50 mM HEPES, pH 7.5, 100 mM NaCl). The controls
had no inhibitor added to the reactions. 50 μL of 62 μM CDO was diluted with
HEPES buffer with cysteine. The cysteine concentration varied from 0 mM to 13.9
mM over eight reactions. There were two tests done, one with aspartate as the
inhibitor and one with acetate as another inhibitor. These tests had the same CDO and
cysteine concentrations but also added were the inhibitors to their respective reactions
to a final concentration of 9 mM. Reactions were incubated for about 3 hours and 50
minutes. Assays were analyzed on the HPLC as the protocol stated above in section
1.2.3.1.
5.2.2 Buffer inhibition assay
CDO was buffer exchanged into phosphate buffer, ammonium acetate
solution, and HEPES buffer. Two 50 μL aliquots per buffer were added to epi-tubes
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totaling six samples. The samples were reacted and analyzed as stated in the activity
assay protocol above (Section 1.2.4.1) except that aspartate is also added to one of the
tubes per buffer at a final concentration of 2mM.
5.2.3 Metal chelation by aspartate
CDO at a concentration of 200 μM was taken and aliquoted into three 6 mL
volumes. These were buffer exchanged into the three different solutions. The
solutions were phosphate buffer, ammonium acetate solution, and HEPES buffer.
Each of these buffers was 50 mM, pH 7.5 and also contained 100mM NaCl. They
were buffer exchanged and concentrated using 10,000 Da spin concentrators down to
a final volume of 2 mL. After buffer exchanging the three samples were each split
into two aliquots and added to epi-tubes. To one aliquot of each buffer sample,
aspartic acid was added to a final concentration of 2 mM. These were incubated for
15 minutes at room temperature. The six samples were then buffer exchanged into
their respective buffers to remove any aspartic acid and unbound metal. The samples
were then analyzed for iron content on an ICP-OES.
5.2.4 Retesting of previously found inhibitors in HEPES buffer
A selection of the previously investigated inhibitors were experimented in
HEPES buffer. The compounds selected were homocysteine, α-ketoglutarate, and Scarboxymethyl-cysteine. The reaction conditions 500 μL of 30 mM cysteine and 450
μL of 30 mM inhibitor were added to 50 μL of CDO. The assay conditions were the
same as previously said above by incubation in 37 oC water bath for 4 hours.
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5.3 Results
A number of different buffers were used through out the experiments during
the studying of CDO by the current student as well as previous students. The three
solutions were phosphate, ammonium acetate solution, and HEPES. All of them were
pH 7.5 and also contained 100mM NaCl. The effect of the buffer was put into
question when it was found that in HEPES, aspartic acid acted as an activator. This
was odd because it was previously found previously that aspartic acid was an
inhibitor.1 The experiments that found that aspartic acid was an inhibitor utilized the
phosphate buffer.
The aspartate inhibition assay was conducted to determine what type of
inhibitor it was. The results of the assay concluded that aspartate was in fact an
activator instead of inhibitor. Aspartate at high concentrations of cysteine increased
activity by approximately 8% compared to wild type CDO without aspartate. The
acetate portion of this assay inhibited CDO by approximately 40%.
When assays were conducted in the various buffers stated above it was found
that in HEPES aspartic acid actually acts as a slight activator. It increased activity by
8%. In phosphate and ammonium acetate solution aspartic acid was found to be an
inhibitor. Aspartic acid inhibited activity by 18% and 63% in phosphate buffer and
ammonium acetate solution respectively. It was thought that aspartate may be
chelating the iron and extracting it out of CDO. The results from the metal analysis
from the chelating experiment found that the samples of CDO in HEPES buffer
contained 14.9% iron and 15.9% with aspartate. CDO in phosphate buffer and
ammonium acetate solution had a decrease in iron content when aspartate was added
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from 14.5% to 12.3% and 14.3% to 7.0%. This correlates to an increase in iron in
HEPES buffer by 6.7% and a decrease by phosphate buffer and ammonium acetate
solution by 15.1% and 51.0% respectively.
Several compounds that were previously found to be inhibitors were retested
in HEPES buffer. The various compounds tested and found to be inhibitors were
homocysteine, mercaptopropionic acid, aspartic acid, α-ketoglutarate, and Scarboxymethyl-cysteine. These inhibition assays were performed in phosphate buffer.
In the retest it was found that homocysteine, S-carboxymethyl-cysteine, and αketoglutarate had an increase in activity by 26.1%, 43.4%, 44.2% respectively when
compared to wild type CDO with just cysteine present. The rates and their percent
activities compared to wild type CDO with no activator/inhibitor added can be seen in
table 5.1. Cysteamine caused no appreciable increase or decrease in activity.
Table 5.1. Activity increases exhibited by CDO with various activators in HEPES
buffer, pH 7.5
Retested
Rates (mol CSA/min)
Percent activity (Compared to
activators/inhibitors
Wild type)
No activator/inhibitor 38.2±7.2
100%
Homocysteine
48.2±6.5
126.1%
S-carboxymethyl54.8±9.3
143.4%
cysteine
α-ketoglutarate
55.1±8.6
144.2%

5.4 Discussion
In the past it was determined that structural analogs of cysteine with a
negative side chain had the ability to inhibit CDO activity. In various tests that were
conducted recently it appears that these analogs may not be inhibitors. In fact they
activated CDO. A reexamination of the inhibitor aspartate was performed to
determine what type of inhibitor it was. These experiments revealed that aspartate is
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an activator in the HEPES buffer, pH 7.5. Then another test, the buffer inhibition test,
confirmed that aspartate is an activator in HEPES, but it is also an inhibitor in
phosphate buffer and ammonium acetate solution.
At first this was confusing because there weren’t many indications of what
could be happening chemically. Then it was thought that aspartate could be chelating
the metal and facilitating removal from the enzyme. After the metal is pulled out the
phosphate or acetate can bind to it and keep it from loading back into the enzyme.
The negative charges on the ions have the ability to ligate the metal.
To test this theory the aspartate chelating experiment was done. The enzyme
was incubated with aspartate in phosphate buffer to rip out the metal and then buffer
exchanged for metal analysis. This was compared to enzyme that was not subjected to
aspartate. The findings support that aspartate may be facilitating iron removal and
then the ligation by phosphate keeps it from reentering the binding site.
As stated above in the results section it was found that the addition of
aspartate to HEPES buffer increased the iron content from 14.9% to 15.9%. In the
other two buffers the aspartate caused a drop in iron from 14.5% to 12.3% and 14.3%
to 7.0% in the phosphate and acetate buffers respectively. This correlated to an
increase in iron in HEPES buffer by 6.7% and a decrease by phosphate and acetate
buffers by 15.1% and 51.0% respectively. These percentages are very similar to that
of the changes in activity. In HEPES buffer the aspartate caused an increase of 8%
and a decrease of 18% and 63% in phosphate and acetate respectively. These results
support the hypothesis that aspartate aids in iron removal from CDO in phosphate and
acetate buffers illustrated in figure 5.1. Thus, when the samples were buffer
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exchanged the metal bound to aspartate and the ion could be washed out lowering the
amount of metal in solution. In the case of phosphate it is possible that the metal was
also removed via precipitation due to the insolubility of iron (II) phosphate.
Fe-CDO

Fe + CDO
Aspartate with
Acetate or Phosphate
Fe Complex + CDO

Figure 5.1 Iron equilibrium when aspartate is introduced into reaction.
Metal loading of the enzyme was previously done in ammonium acetate
buffer because iron (II) phosphate would form in the phosphate buffer and it is
insoluble, but because ammonium acetate is not truly a buffer at pH 7.5 it was still not
preferred. Thus, HEPES buffer is currently used to load the enzyme with iron.
Then there is the question of whether the other previously found inhibitors
were in fact still inhibitors in HEPES buffer. Thus, the purpose of the retesting was to
determine if the inhibitors found previously are infact still inhibitors in the HEPES
buffer. These compounds are structural analogs of cysteine and also contain a
negative side chain. It was found that structural analogs without the negative side
chain had no affect on CDO activity. In the retesting it was found that the structural
analogs that were once inhibitors actually had activating qualities in the HEPES
buffer. α-ketoglutarate had the largest increase in activity but S-carboxymethylcysteine follows closely behind by about one percent.
The activation of CDO by these cysteine analogs gives clues into how the
reaction mechanism occurs. One hypothesis is that multiple cysteine molecules
maybe bound in the active center and the cysteine that is actually converted to CSA
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may not be bound directly to the iron. One cysteine is bound to the iron and the
cysteine that is reacted with oxygen is apart of a hydrogen-bonding network with
various residues and the cysteine bound to the iron. The activating compounds with
the negative side chains may be able to find its way into the active site and bind to the
iron more tightly than cysteine. Thus the reaction can occur more quickly when these
activators are present.
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